2426665-56-5

2426665-56-5 structure
2426665-56-5 structure
  • Name: Tubulin polymerization-IN-13
  • Chemical Name: Tubulin polymerization-IN-13
  • CAS Number: 2426665-56-5
  • Molecular Formula: C20H21NO6
  • Molecular Weight: 371.38
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2022-10-11 18:19:49
  • Modify Date: 2025-08-27 11:16:50
  • Tubulin polymerization-IN-13 (Compound 4f) is a tubulin polymerization inhibitor (IC50=0.37 μM). Tubulin polymerization-IN-13 shows anti-proliferative activity against cancer cells, induces apoptosis and potential antivascular activity[1].

Name Tubulin polymerization-IN-13
Description Tubulin polymerization-IN-13 (Compound 4f) is a tubulin polymerization inhibitor (IC50=0.37 μM). Tubulin polymerization-IN-13 shows anti-proliferative activity against cancer cells, induces apoptosis and potential antivascular activity[1].
Related Catalog
Target

IC50: 0.37 μM (tubulin polymerization)[1]

In Vitro Tubulin polymerization-IN-13 (0.005-2.8 nM) treatment inhibits tumor cell proliferation[1]. Tubulin polymerization-IN-13 (8.7-10 μM) is non-toxic in non-tumor cells[1]. Tubulin polymerization-IN-13 (1-50 nM; 24 h) treatment induces cell cycle arrest in G2/M[1]. Tubulin polymerization-IN-13 (10 nM; 24 and 48 h) treatment induces cell apoptosis[1]. Tubulin polymerization-IN-13 (10-100 nM; 24 h) treatment induces alteration of the microtubule network[1]. Cell Proliferation Assay[1] Cell Line: HeLa, HT-29, Daoy, HL-60, SEM, and Jurkat cells Concentration: 0.005-2.8 nM Incubation Time: Result: Showed IC50s of 2.8 nM, 2.1 nM, 0.005 nM, 2.7 nM, 0.31 nM, and 0.28 nM for HeLa, HT-29, Daoy, HL-60, SEM, and Jurkat cells, respectively. Cell Cytotoxicity Assay[1] Cell Line: Peripheral blood lymphocytes (PBL) Concentration: 8.7-10 μM Incubation Time: Result: Showed a GI50 of 8.7 μM in quiescent lymphocytes. Cell Cycle Analysis[1] Cell Line: HeLa cells Concentration: 1, 5, 10, and 50 nM Incubation Time: 24 hours Result: Induced a G2/M arrest at 10 nM, increased G2/M cells accompanied by a strong reduction of cells in the G1 phase. Apoptosis Analysis[1] Cell Line: HeLa cells Concentration: 10 nM Incubation Time: 24 and 48 hours Result: Induced caspase-9 activation, PARP cleavage, Bcl-2 phosphorylation and Mcl-1 downregulation. Immunofluorescence[1] Cell Line: HeLa cells Concentration: 10, 50, and 100 nM Incubation Time: 24 hours Result: Showed the disorganization of microtubules at 10 nM, and much more evident at 50 and 100 nM.
In Vivo Tubulin polymerization-IN-13 (intraperitoneal injection; 15 or 5 mg/kg; once every other day; 4 times) reduces tumor growth in a dose-dependent manner in an orthotopic murine tumor model[1]. Animal Model: Seven-week-old C57BL/6 female mice orthotopically injected into the mammary fat pad with E0771 mammary carcinoma cells[1] Dosage: 15 or 5 mg/kg Administration: Intraperitoneal injection; 15 or 5 mg/kg; once every other day; 4 times Result: Reduced tumor mass by 45.7% and 16.9% at 15 and 5 mg/kg, respectively. Showed no sign of toxicity and no decreasement in animal body weight.
References

[1]. Paola Oliva, et al. Design, synthesis, in vitro and in vivo biological evaluation of 2-amino-3-aroylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors. Eur J Med Chem. 2020 Aug 15;200:112448.

Molecular Formula C20H21NO6
Molecular Weight 371.38
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.